A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer's Disease
Latest Information Update: 05 Jul 2025
At a glance
- Drugs Buntanetap (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Sponsors Annovis Bio
Most Recent Events
- 21 Mar 2025 According to an Annovis Bio media release, The symptomatic data is anticipated in mid-2026, followed by the disease-modifying data in mid-2027.
- 05 Feb 2025 Planned initiation date changed from 1 Jan 2025 to 1 Feb 2025.
- 05 Feb 2025 Status changed from not yet recruiting to recruiting.